secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001213900-24-061942
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron receives FDA Fast Track designation for Lomecel-B in mild Alzheimer's
--------------------------------------------------------------------------------

- FDA Fast Track designation granted for Lomecel-B (allogeneic cell therapy) to treat mild Alzheimer’s disease.
- Second FDA special designation for Lomecel-B in Alzheimer's, following RMAT designation on July 9, 2024.
- Fast Track enables Priority Review (6-month review) and rolling submission; fifth overall special designation.
- Phase 2a CLEAR MIND data showed overall slowing/prevention of disease worsening versus placebo.
- Full results to be presented at AAIC 2024 (July 28–Aug 1) in Featured Research Session and poster.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024061942/0001213900-24-061942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024061942/ea0209541-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-061942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer